Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 11/20 | 0.63 |
| ▸ | ADCY6 | O43306 | 3/20 | 0.59 |
| ▸ | ADCY3 | O60266 | 3/20 | 0.59 |
| ▸ | ADCY9 | O60503 | 3/20 | 0.59 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.59 |
| ▸ | ADCY8 | P40145 | 3/20 | 0.59 |
| ▸ | ADCY7 | P51828 | 3/20 | 0.59 |
| ▸ | ADCY2 | Q08462 | 3/20 | 0.59 |
| ▸ | ADCY1 | Q08828 | 3/20 | 0.59 |
| ▸ | ADCY4 | Q8NFM4 | 3/20 | 0.59 |
| ▸ | GCG | P01275 | 9/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655296 | 0.91 | GCGR (0.76) | GCGRGCG | |
| SCHEMBL3276719 | 0.90 | GCGR (0.52) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL2654904 | 0.86 | GCG (0.56) | GCGRGCG | |
| SCHEMBL2656546 | 0.86 | NR1H4 (0.52) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL21528652 | 0.84 | GCGR (0.63) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL21528649 | 0.84 | GCGR (0.63) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL21545018 | 0.84 | GCG (0.57) | GCGRGCG | |
| SCHEMBL21562796 | 0.84 | GCG (0.55) | GCGRGCG | |
| SCHEMBL2662314 | 0.81 | CA1 (0.51) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL21544944 | 0.81 | GCG (0.63) | GCGRGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951661-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2012-08-08 | — | — | EP | claimed |
| US-7696248-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | claimed |
| US-20080300308-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-04 | — | — | US | claimed |
| EP-1951661-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007106181-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-09-20 | — | — | WO | claimed |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| EP-1951661-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1951661-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2012-08-08 | — | — | EP | disclosed |
| US-7696248-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696248-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696248-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080300308-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-04 | — | — | US | disclosed |
| US-20080300308-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-04 | — | — | US | disclosed |
| US-20080300308-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-04 | — | — | US | disclosed |
| EP-1951661-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007106181-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106181-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300308-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | GCGR 2/4885ADCY6 214/4885ADCY3 208/4885 |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885ADCY6 555/4885ADCY3 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.